ABSTRACT Background: cJun terminal kinase (JNK) is constitutively activated in most hepatocellular carcinomas (HCCs), yet its exact role in carcinogenesis remains controversial. While tumour necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL) is known as a major mediator of acquired immune tumour surveillance, and is currently being tested in clinical trials as a novel cancer therapy, the resistance of many tumours to TRAIL and concerns about its toxicity in vivo represent obstacles to its clinical application. In this study we investigated whether JNK activity in HCC could contribute to the resistance to apoptosis in these tumours. Methods: The effect of JNK/Jun inhibition on receptormediated apoptosis was analysed by pharmacological inhibition or RNA interference in cancer cells and nontumour cells isolated from human liver or transgenic mice lacking a phosphorylation site for Jun. Results: JNK inhibition caused cell cycle arrest, enhanced caspase recruitment, and greatly sensitised HCC cells but not normal hepatocytes to TRAIL. TRAILinduced activation of JNK could be effectively interrupted by administration of the JNK inhibitor SP600125. Conclusions: Expression and TRAIL-dependent feedback activation of JNK likely represent a mechanism by which cancer cells escape TRAIL-mediated tumour surveillance. JNK inhibition might represent a novel strategy for specifically sensitising HCC cells to TRAIL thus opening promising therapeutic perspectives for safe and effective use of TRAIL in cancer treatment.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and its incidence is rising. To date, surgery is the only curative treatment available for those who qualify. The majority of patients, however, are not suitable candidates for surgery, and curative medical treatment is currently not available. Therefore, new therapeutic approaches are needed. 1 Loss of sensitivity to apoptosis is a hallmark of cancer. This is thought to occur through several mechanisms including loss of the death receptors TRAIL-R or CD95, or impairment of intracellular signalling pathways. 2 Previous studies demonstrated enhanced primary tumour and metastases formation in mice after TRAIL-receptor blockage or in TRAIL-receptor knock-out mice; 3 clinical studies have furthermore shown a correlation between loss of death receptors and dedifferentiation, tumour size, poor prognosis, and tumour recurrence. 4 We have also recently shown that over-expression of the TRAIL-binding soluble decoy receptor osteoprotegerin (OPG) correlates with tumour stage and metastasis formation in patients affected by colon carcinoma. 5 Activation of apoptosis signalling pathways in cancer cells otherwise resistant to apoptosis is therefore an important therapeutic strategy.
Due to its ability to induce apoptosis in cancer cells while leaving normal cells unharmed, TRAIL has become a promising candidate for tumour therapy. 6 7 While in vitro toxicity of TRAIL to non-tumour tissues varies greatly, depending on the experimental design and the type of TRAIL used, 8 9 recent clinical trials seem to confirm the safety of TRAIL administration in vivo. [10] [11] [12] In spite of these reassuring results, concerns about the safety of systemic administration of TRAIL remain, especially with regards to possible toxic effects on diseased organs. 13 14 A second, relevant, limitation to a therapeutic use of TRAIL is the resistance of about 50% of cancer cells to the activation of the receptormediated apoptotic pathway. 15 Consequently, a future clinical use of TRAIL will have to confront the challenge of sensitising cancer cells to this molecule as well as minimising its cytotoxic effect on normal tissues. This prompts a reconsideration of known carcinogenic signal pathways regarding their contribution to resistance to receptor-mediated apoptosis. [16] [17] [18] Through the phosphorylation of c-Jun and its activating protein-1 (AP-1) transcription activity, cJun N-terminal kinase (JNK) regulates a wide spectrum of cellular activities in physiological conditions and has been shown to act pro-and anti-apoptotically in different cell types and experimental systems 19 20 (for a review, see the excellent work by Czaja 19 ). The fact that JNK might play a role in the pathogenesis of tumours is supported by the fact that this kinase is constitutively expressed in several tumours and in most hepatocellular carcinomas. [21] [22] [23] [24] [25] The mechanisms through which JNK signalling affects the pathogenesis of tumours remain elusive, however.
We hypothesised that over-expression of JNK/ Jun in HCC contributes to the pathogenesis of tumours by specifically interfering with receptorinduced apoptosis. Targeting JNK might therefore represent the key to the successful use of TRAIL as a cancer treatment. Austria), HepA1-6 cells were cultured in DMEM (Gibco BRL, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin (Gibco BRL). Tissue sample collection from human liver resections was performed according to the guidelines of the charitable state-controlled foundation Human Tissue and Cell Research (Regensburg, Germany). 26 Human hepatocytes were isolated using a modified two-step EGTA/collagenase perfusion procedure as described previously. 27 Mouse hepatocytes were isolated from A/A mice, lacking the phosphorylation site for c-Jun 28 or from syngenic wild-type mice. Cell viability, as determined by trypan blue exclusion, was typically .90%. Cells were plated on 6-well plates (5610 5 cells/well) or 12-well plates (2610 5 cells/well, Biocoat; Becton Dickinson, Heidelberg, Germany) in William's E Medium (Gibco) containing 10% FCS (Gibco), 1% penicillin/ streptomycin and supplemented with cystein (90 mg/l) and methionin (55 mg/l). Cells were stimulated after overnight incubation. The JNK-and non-coding sequences used for siRNA transfection have been described previously. 25 For c-Jun the following sequences were used. Sense: 59-AAAAAAGGAAGCT GGAGAGAAT-39; antisense: 59-ATTCTCTCCAGCTTCCT TT-39. For transient transfection Oligofectamine (Invitrogen, Carlsbad, California, USA) was used according to the manufacturer's instructions.
Reagents
SP600125 was purchased from Tocris (Bristol, UK) and dissolved in dimethyl sulfoxide (DMSO). Anti-Apo1 antibody and LZCD95L were a kind gift of P Krammer (DKFZ, Heidelberg, Germany). TRAIL (Apo-2L, human recombinant) was purchased from Sigma (Taufkirchen, Germany; cat. number K4761-20UG). The pancaspase inhibitor Z-VAD-FMK was purchased from Promega (Mannheim, Germany), the caspase 8 inhibitor Z-IETD-FMK and the caspase 9 inhibitor Z-LEHD-FMK were purchased from BD Pharmingen (San Diego, California, USA); all were diluted in DMSO and added at the concentration of 20 mmol/l.
Incubation of Chang cells with SP600125 also caused a G2/M cell cycle arrest. Fluorescence-activated cell sorting (FACS) analysis of DNA content showed a G2-phase cell cycle arrest after 24 h of treatment with SP600125, compared to cells treated with DMSO (p,0.005) ( fig 1C) . 
Apoptosis and membrane receptor assessment
Apoptosis and cell cycle were analysed by assessing sub-G1 events or the respective cell cycle phases in the euploid cell fraction, using flow cytometry (FACScalibur, using Cell Quest software; Becton Dickinson) according to Nicoletti et al. 29 Additionally, apoptosis was assessed morphologically by Hoechst 33342 staining (Sigma Chemical, Diesenhofen, Germany) and fluorescence microscopy (Carl Zeiss, Jena, Germany). The validity of FACS results in primary hepatocytes was confirmed by comparing the number of apoptotic cells observed after Hoechst staining (500 cells from four randomly chosen fields per treatment group), with sub-G1 events counted in FACS analysis. This comparison was done in triplicate using cells from two different donors. For assessment of membrane receptors, cells were detached from the plates by ethylenediaminetetraacetic acid (EDTA), washed and incubated for 1 h with the following monoclonal fluorescein isothiocyanate (FITC)-coupled antibodies: CD95 (556640) from BD Pharmingen, TRAIL-R1 (ALX-804-297F-T100), TRAIL-R2 (ALX-522-005FC050) and control mIgG1 (Alexis, San Diego, California, USA).
Western blot analysis
Briefly, proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidine difluoride (PVDF) membranes. After blocking for 1 h in 5% milk-Tris-buffered solution(TBS)-Tween solution, membranes were incubated with primary antibodies at 4uC overnight, followed by the appropriate secondary antibody for 1 h at room temperature. Bands were visualised using the analysis was carried out using TINA software (Raytest, Straubenhardt, Germany).
Fast activated cell-based ELISA (FACE)
The phospho-JNK FACE kit was purchased from Active Motif (Carlsbad, California, USA). Three thousand cells per well were seeded overnight in 96-well plates. Cells were stimulated as indicated, then fixed in 4% formalin and plates were stored at 4uC. Incubation with primary and secondary antibody and standardisation for cell count using in-well crystal violet stain was done according to the manufacturer's instructions.
Statistics
For statistical evaluation the t test for independent samples has been used. Differences have been regarded as significant for p values at least less than 0.05 and were indicated in each figure.
Unless otherwise specified, all values represent the mean and standard deviation of triplicate values from the same 
RESULTS

JNK inhibition enhances receptor-mediated apoptosis and causes cell cycle arrest
To evaluate the effects of JNK inhibition on receptor-mediated apoptosis in hepatocellular carcinoma, we used Chang cells as a model system. Cells were treated with TRAIL, the CD95 agonistic antibody anti-Apo1 or with the JNK inhibitor SP600125 as indicated. The efficacy of SP600125 as JNK inhibitor was confirmed by the inhibition of methyl methane sulfonate (MMS)-induced c-Jun phosphorylation ( fig 1A) . While Chang cells proved resistant to TRAIL, anti-Apo1 or to SP600125 alone ( fig 1A,B) , addition of SP600125 synergistically increased apoptosis rates triggered by TRAIL or anti-Apo1 (ie, apoptosis increased from 7% to 55% after stimulation with TRAIL at the concentration of 25 ng/ml). After 16 h of incubation with SP600125 and TRAIL or anti-Apo1, Chang cells displayed the characteristic morphological features of apoptosis, such as cell shrinkage and membrane blebbing. Hoechst staining of the same cells showed typical nuclear fragmentation (fig 2A-F) .
Sensitisation of hepatoma cells to apoptosis by SP600125 is a specific effect of JNK inhibition and is independent of cell line and p53 status
To rule out the possibility that the increased sensitivity to apoptosis could be due to non-specific effects of SP600125 on kinases other than JNK, we additionally targeted JNK by specific interfering RNA sequences ( fig 3A) . JNK inhibition by siRNA alone did not induce significant apoptosis, but clearly increased the pro-apoptotic effect of TRAIL-receptor (TRAIL-R) and CD95 stimulation ( fig 3B) . This confirms that JNK activity does not affect basal apoptosis, but acts to suppress apoptosis mediated by membrane receptors.
Similarly to the effect observed in Chang cells, the combination of SP600125 and anti-Apo1 or TRAIL also induced apoptosis in HepG2 and Huh7 hepatoma cells ( fig 3C) . As expected, due to the lack of a functional CD95 receptor in this cell line, SP600125 only increased TRAIL-induced apoptosis, but failed to enhance CD95-mediated apoptosis in Huh7. 30 Thus, we conclude that JNK inhibition sensitises hepatoma cells to apoptosis, and is not cell-line specific. The fact that SP600125 greatly increases TRAIL sensitivity of Huh7 cells, which carry a mutated p53, also shows that the effect of JNK inhibition on apoptosis is not dependent on p53 status.
TRAIL-R-and CD95-mediated JNK activation represents a negative feedback mechanism that interferes with receptorinduced apoptosis in hepatoma cells
To assess the effect of the pro-apoptotic receptor stimulation on JNK activity we used ELISA to measure the extent of JNK activation in Chang cells, 1 h after stimulation with increasing doses of TRAIL. As shown in fig 4A, stimulation of Chang cells with TRAIL showed a dose-dependent increase of phosphorylation and thereby activation of JNK, while the total amount of JNK remained unaffected ( fig 4A) . Subsequently, we also assessed the time dependency of JNK activation and the total amount of JNK by measuring phosphorylated JNK (p-JNK) levels at different time points after stimulation. Incubation of Chang cells with 5 ng TRAIL or 100 ng anti-Apo1 resulted in an early increase of p-JNK levels which peaked after stimulation and progressively diminished over 5 h. Simultaneous administration of SP600125 effectively reduced TRAIL and anti-Apo1-induced JNK phosphorylation (fig 4B) , without affecting overall expression of JNK ( fig 4C) . Thus, TRAIL-R-and CD95-mediated JNK activation is likely to represent a negative feedback mechanism by which hepatoma cells become resistant to receptor-induced apoptosis. To evaluate whether the sensitivity to JNK inhibition is due to JNK over-expression, and/or constitutive activation of JNK in our in vitro system, the amount of p-JNK in Chang, HepG2 and Huh7 hepatoma cell lines was assessed by western blot in comparison to that of primary cultivated hepatocytes. In agreement with data from primary tumours, 22 the level of p-JNK in the cell lines used in our system was remarkably elevated in comparison to that 
c-Jun inhibition enhances receptor mediated apoptosis
To investigate whether JNK exerts its anti-apoptotic affect through activation of c-Jun and AP-1 transcriptional activity 24 we also targeted c-Jun with specific RNA interference. siRNA transfection of HepG2 cells with c-Jun siRNA effectively decreased c-Jun at the protein level ( fig 5A) . RNA interference also led to a 10-fold decrease of the AP-1 transcription activity, as determined by reporter luciferase activity 24 h after transfection ( fig 5A) . siRNA transfection, application of 10 ng/ml of the CD95 ligand (LZCD95L) or of 2.5 ng/ml TRAIL for 16 h did not significantly affect apoptosis rates. However, apoptosis greatly increased up to 64% and 69% when the CD95 ligand or TRAIL were administered in cells previously transfected with c- Jun-targeting siRNA (fig 5B) . Thus, inhibition of c-Jun resulted in a similar pro-apoptotic effect as inhibition of JNK suggesting that c-Jun/AP-1 transcriptional activity contributes to the pro-apoptotic effect observed after JNK inhibition.
Inhibition of MAPK facilitates receptor-mediated activation of caspase 8, independently of membrane receptor expression
To determine the level of interaction between JNK inhibition and the receptor-mediated pro-apoptotic pathway, caspase cleavage was assessed. Co-treatment of Chang cells with SP600125 and TRAIL or anti-Apo1 increased activation of both caspase 3 and 8. Early appearance of cleaved fragments of caspase 8 demonstrates that caspase 8 activation is an early event in the induction of apoptosis, and not a feedback phenomenon occurring at later time points (fig 6A,B) . To further investigate the interaction between JNK and caspase activation we analysed the effects of several caspase inhibitors on the synergistic effect of SP600125 and TRAIL or anti-Apo1. The pancaspase inhibitor Z-VAD-FMK abolished any apoptotic effect of TRAIL and anti-Apo1, even when combined with SP600125. A similar effect could be observed after administration of the caspase 8 inhibitor Z-IETD-FMK. Incubation with the caspase 9 inhibitor Z-LEHD-FMK also significantly reduced apoptosis rates triggered by combined treatment of Chang cells with SP600125 and TRAIL or anti-APO1 (fig 6C) . This clearly demonstrates that increased recruitment of caspase 8 after TRAIL-receptor or CD95 stimulation is an essential mechanism by which JNK inhibition sensitises hepatoma cells to apoptosis. The fact that caspase 9 activation also contributes to TRAIL and anti-Apo1-induced apoptosis after JNK inhibition is in agreement with the notion that hepatocytes are type 2 cells, ie, are capable of reinforcing apoptotic signalling initiated by the membrane receptors through the recruitment of the mitochondrial pathway.
Since loss of membrane receptors plays a role in carcinogenesis, 31 32 and several chemotherapeutic drugs have been shown to increase expression of death receptors, 33 we assessed whether the increased caspase 8 recruitment observed after JNK/Jun inhibition could be due to an increase of surface receptor expression. As judged by FACS analysis, treatment with SP600125 did not lead to an increase of membrane receptors. Instead, a significant decrease of CD95 and TRAIL-R2 (fold decreases of 0.69 (SD 0.1) and 0.58 (SD 0.1), respectively; p,0.05), but not of TRAIL-R1 could be detected (fig 7) . This indicates that JNK inhibition sensitises hepatoma cells to apoptosis by affecting the intracellular apoptotic signalling pathways.
Inhibition of JNK does not sensitise primary human hepatocytes to receptor-mediated apoptosis
To assess whether the effect of JNK inhibition is specific for cancer thus representing a feasible therapeutic option for HCC, we also evaluated the effect of JNK inhibition on sensitivity to TRAIL of normal cells. To this end, primary normal human hepatocytes, cultivated for 1 day after liver perfusion, were incubated with anti-Apo1 or TRAIL in the presence or absence of SP600125. As reported previously, 9 hepatocytes proved highly sensitive to CD95 stimulation ( fig 8A) . In contrast, a concentration of 5 ng/ml of TRAIL only marginally reduced cell viability. In both cases, concomitant JNK inhibition by SP600125 did not increase apoptosis ( fig 8B) as judged by FACS analysis, morphological features of cells and Hoechst nuclear staining (fig 8C-F) . JNK activity therefore strongly influenced the sensitivity to apoptosis inducing surface receptors cancer cells, but not in normal cells.
Sensitivity of primary mouse hepatocytes to receptor-mediated apoptosis is independent of c-Jun phosphorylation and JNK activity
Since no specific pharmacological inhibitor of c-Jun is available to assess the effect of the mitogen-activated protein kinase (MAPK) inhibition downstream of JNK, we compared the sensitivity to CD95 stimulation in hepatocytes isolated from wild-type mice with that of hepatocytes obtained from mice carrying a mutation at the site of c-Jun phosphorylation (JunA/ A). 28 Confirming that c-Jun phosphorlyation does not affect CD95-mediated cell death in normal cells, basal apoptosis rates in hepatocytes isolated from JunA/A mice did not differ from that observed in cells isolated from wild-type mice. Moreover, administration of the murine CD95 agonistic antibody Jo-2 hepatocytes, isolated from mice expressing the mutated form of c-Jun lacking the activating phosphorylation site (AA) or wild-type (wt) mice were seeded in collagen-coated 12-well plates and allowed to attach for 2 h. Apoptosis rates were determined by measuring sub-G1 events using FACS analysis 16 h after stimulation. The graph shows mean apoptosis rates and SD of one representative experiment, performed in triplicate, and repeated at least three times. (A) Apoptosis rates in hepatocytes isolated from A/A mice and from wild-type after incubation with 100 ng/ml of the mouse CD95 agonistic antibody Jo-2 for 16 h or incubated with medium alone. (B) Apoptosis rates in wild-type hepatocytes after stimulation with Jo-2 alone or in combination with SP600125. (C) Apoptosis rates of HepA1-6 mouse hepatoma cells, 16 h after treatment with SP600125, Jo-2 or a combination of both (*p,0.01; {NS). DMSO, dimethyl sulfoxide; JNK, cJun -N-terminal kinase; SP, SP600125. triggered apoptosis in hepatocytes from JunA/A mice at the same rate as in wild-type hepatocytes ( fig 9A) . JNK inhibition by SP600125 also did not affect apoptosis rates ( fig 9B) . Failure to sensitise mouse cells was not due to a species specific effect of SP600125 in human cells, because SP600125 greatly sensitised HepA1-6 mouse hepatoma cell line to the action of Jo-2 ( fig 9C) .
DISCUSSION
JNK is constitutively active in many tumours and in as many as 75% of hepatocellular carcinomas. The mechanism by which this kinase contributes to the carcinogenesis of tumours, however, still remains largely an object of debate 19 34 35 We show here how inhibition of JNK affects proliferation and apoptotic properties of hepatocellular carcinoma cells, making the targeting of this signalling pathway a potential target for the treatment of these tumours.
TRAIL exerts a primary role in the surveillance of tumour formation as demonstrated by several animal models as well as clinical data. We also recently reported that the over-expression of OPG, a decoy receptor for TRAIL regulated by b-catenin, in patients affected by colorectal carcinoma correlates with tumour stage and metastasis formation. 5 In our system JNK inhibition caused cell cycle arrest and sensitised cancer cells to TRAIL-mediated apoptosis. TRAIL administration resulted in the increase of JNK activity and this effect could be reverted by administration of SP600125. This suggests that early JNK activation upon TRAIL administration represents a negative feedback mechanism of apoptosis inhibition in cancer cells. It is therefore likely that the frequently observed over-expression of JNK in cancer cells 24 results from the selection of clones resistant to endogenous TRAIL following a gain of function of JNK as negative regulator of apoptosis. The association of SP600125 and TRAIL synergised to induce apoptosis selectively in cancer cells. Thereby anti-tumour concentrations of TRAIL could be tapered to low doses. Thus, JNK inhibition might also improve both efficacy and safety of TRAIL administration for therapeutic purposes.
Treatment of Chang cells with SP600125 led to increased recruitment and activation of caspase 8 upon the stimulation of the death receptors. However, increased caspase 8 recruitment was not due to an increase of the quota of TRAIL receptor or CD95 on the cell membranes. Expression of TRAIL-R1, TRAIL-R2 and CD95 on the cell surface was not increased as a consequence of JNK inhibition; instead, a decrease of TRAIL-R2 and of CD95 could be detected (fig 7) .
Our findings describing an anti-apoptotic role for JNK are in contrast to previous data showing that JNK can also act as mediator of apoptosis: prolonged JNK activation has been shown to be the essential mediator of cell death in response to TNF and oxidative stress in non-transformed cells. 19 20 Furthermore, several publications showed recently that JNK might act pro-apoptotically, mediating cell death triggered by TRAIL in diseased, non-transformed hepatocytes as a consequence of several pathological situations such as adenoviral hepatitis, 36 hepatitis C virus hepatitis, 37 cholestatic liver disease 38 and non-alcoholic steatohepatitis. 39 Our finding that JNK inhibition acts to enhance apoptosis in liver tumours suggests that JNK in the liver might have different roles in non transformed cells under stress conditions 14 19 20 and in cancer cells.
A different effect of JNK inhibition in cancer cells and in nontumour cells is likely to have relevant clinical significance: liver cancer arises in most cases in the context of a diseased liver where JNK, as shown by the aforementioned papers, acts pro-apoptotically to mediate TRAIL toxicity. Use of JNK inhibitors to sensitise cancer cells to TRAIL might open the way for the use of TRAIL in the therapy of liver tumours, since their use may reduce liver damage and TRAIL toxicity in nontumour tissues while sensitising malignant cells to TRAIL. Remarkably, in many of the recent works investigating the mechanism of TRAIL toxicity in non-tumour cells showed that the pro-apoptotic effect of TRAIL was mediated in these cells by increased TRAIL-R2 in adenoviral hepatitis, 36 bile-acid-induced TRAIL sensitisation 38 and in liver steatosis; 39 this is in agreement with the fact that in our system JNK inhibition reduced the expression of TRAIL-R2 and of CD95 but not that of TRAIL-R1 ( fig 7) ; however, reduction of TRAIL-R2 did not impair the proapoptotic effect of TRAIL in cancer cells, suggesting that JNK might act to reduce TRAIL toxicity in normal cells by decreasing the amount of TRAIL receptors on the cell membranes while sensitising cancer cells by enhancing the intracellular signalling of TRAIL.
Inhibition of JNK signalling effectively sensitised tumour cells to TRAIL independently of the tumour suppressor p53 (fig 3) . Mutations of p53 occur in approximately 50% of all human tumours 40 and represent a major cause of tumour resistance to therapy. 41 Therefore inhibition of the MAPK signalling pathway combined with administration of TRAIL could overcome frequent mechanisms of resistance to traditional chemotherapy.
In summary, these data shed new light on how the frequent hyperactivation of JNK in HCC is likely to contribute to carcinogenesis by causing resistance to endogenous TRAIL. Also, JNK inhibition promises to address the problems bound to the exogenous administration of TRAIL for therapeutic purposes by sensitising cancer cells to receptor-mediated apoptosis and by reducing its potential toxicity by decreasing the concentrations needed to trigger apoptosis in cancer cells. JNK inhibition might furthermore increase intrinsic resistance of non-transformed cells to TRAIL.
